Heart · 2010 · 68 citations · 22 references
MedicineBiomedical EngineeringCardiologyBiomedical ImagingBiomedical OpticsInterventional CardiologyCoronary Artery DiseaseCoronary Artery ImagingCoronary Artery SurgeryOptical Coherence TomographyPercutaneous Coronary InterventionStent PlacementCoronary Lesion AssessmentCoronary Stent AssessmentCoronary Stent RestenosisEverolimus TreatmentNeointimal Hyperplasia AssessmentStent Apposition AssessmentStent Patency AssessmentVessel Wall Structure
OBJECTIVE: The aim of this study was to evaluate detailed vessel response after everolimus-eluting stents (EES) implantation in human de novo coronary lesions by optical coherence tomography (OCT). DESIGN, SETTING AND PATIENTS: Between November 2008 and October 2009, 25 patients (14 men, 65.5±8.6 years) with de novo native coronary artery lesions were implanted with 30 EES, and OCT was performed at 8 months post-implantation. MAIN OUTCOME MEASURES: Neointimal thickness (NIT) on each strut, strut apposition to the vessel wall, the frequency of struts surrounded by low intensity area and the incidence of intra-stent thrombus were analysed. To evaluate the radial unevenness of NIT, the difference between the maximum and minimum NIT (dNT) was calculated for each cross-section. RESULTS: At 236±39 days after implantation, there were no major adverse cardiac events, nor target vessel revascularisation. A total of 5,931 struts was evaluated by OCT. The median NIT was 80 μm (25th and 75th percentile 50 μm and 140 μm) and average NIT was 100±74 μm. The number of neointima-covered struts was 5,834 (98.4%), and 31 (0.52%) struts showed malapposition without neointimal coverage. The number of struts surrounded by low intensity area was 452 (7.62%). Eleven EES (37%) showed full neointimal coverage. No intra-stent thrombus was detected. The average dNT was 108±77 μm. CONCLUSIONS: Most EES struts were covered with uniform and thin neointima. The frequency of low-intensity neointima was very low, which may be a result of promoted vessel healing. These results may support improved clinical outcomes with EES in clinical trials.
22
Pathological Correlates of Late Drug-Eluting Stent Thrombosis
Aloke V. Finn, Michael Joner, Gaku Nakazawa et al. · Circulation · 2007 · 1.3K citations · Full text
Ik‐Kyung Jang, Brett E. Bouma, Dong-Heon Kang et al. · Journal of the American College of Cardiology · 2002 · 1K citations
Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease
Gregg W. Stone, Ali A. Rizvi, William Newman et al. · New England Journal of Medicine · 2010 · 896 citations · Full text